Baricitinib in Patients with Refractory Rheumatoid Arthritis


This study, awarded the Top Ten Clinical Research Achievement of the 2017 Clinical Research Forum, led by Dr. Mark Genovese of the Stanford University School of Medicine, analyzed a new drug for rheumatoid arthritis and tested it in more than 500 patients with to treat the disease. It was discovered that this new drug is safe and effective, and significantly improves the disease in more than 50% of patients in 12 weeks.

Video credits to Clinical Research Forum YouTube channel





  • Your reaction?
    Angry Angry
    0
    Angry
    Lol Lol
    0
    Lol
    Love It! Love It!
    0
    Love It!
    Nice Nice
    0
    Nice
    Now I Know Now I Know
    0
    Now I Know
    Sad Sad
    0
    Sad
    Surprised Surprised
    0
    Surprised
    Wow! Wow!
    0
    Wow!
    WTF WTF
    0
    WTF

    Baricitinib in Patients with Refractory Rheumatoid Arthritis

    log in

    reset password

    Back to
    log in